Through innovative devices and diagnostics, we deliver value to patients, healthcare professionals, and healthcare systems.
In our endeavor to build an Asia-based precision medicine platform, we seek out strategic equity investments in medical technology companies that can help us achieve this goal.
Our key medical technology investments include:
- Biolidics Limited (Biolidics) is listed on the Singapore Stock Exchange (Catalist Board: 8YY), an associate company which owns one of the world’s most advanced fully automated circulating tumor cell enrichment technology and is developing complete liquid biopsies solutions for clinical use.
- Singapore Institute of Advance Medicine Holdings (SIAMH) is building an advanced proton therapy centre in Singapore.